Dr. Anne-Corinne Beaver, Cancer Survivor & Surgeon
Appalachian Regional Healthcare System is proud to announce the newest addition to Seby B. Jones Regional Cancer Center, the Paxman Scalp Cooling System. Available to patients receiving chemotherapy treatments for solid tumor cancer, our goal is to help our patients look and feel their best while fighting a difficult battle. The Appalachian Regional Healthcare Foundation raised private funds to bring this technology to the Cancer Center.
What is Paxman Scalp Cooling?
Chemotherapy drugs used to treat solid tumor cancer work by targeting all of the body’s rapidly dividing cells. Since hair is the second fastest dividing cell in the body, hair-loss is an inevitable side effect of chemotherapy. Paxman Scalp Cooling is a procedure that works to prevent hair-loss caused by certain chemotherapy drugs.
How does it work?
Administered through an inner and outer scalp cap during each chemotherapy treatment, Paxman technology lowers the temperature of the scalp by a few degrees before, during, and after treatment. As a result, the three-stage cooling process reduces the blood flow to the hair follicles, minimizing hair loss.
Three-stage scalp cooling process
Is scalp cooling right for me?
When considering a new treatment, patients should evaluate the risks and benefits with their doctor. Paxman Scalp Cooling is not recommended for patients with:
- An existing history or presence of scalp metastasis
- Cancers of the head and neck
- CNS malignancies
- Cold sensitivity
- Hematological malignancies
- Imminent bone marrow ablation chemotherapy
- Previously received, scheduled, or imminent skull irradiation
- Severe liver or renal disease
- Skin cancers
- Small cell carcinoma of the lung
- Solid tumors that have a high likelihood for metastasis in transit
- Squamous cell carcinoma of the lung
How do I get started?
If you have questions or would like to learn more about Paxman Scalp Cooling treatments, call Seby B. Jones Regional Cancer Center at (828) 262-4332 or visit paxmanusa.com.
Share this page
